EKSO · Ekso Bionics Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $1.07M | - | $1.68M | $1.24M | $1.57M | - | $1.92M | $2.31M | $1.80M | - |
| Gross Profit | $1.07M | - | $2.55M | $819.0K | $1.81M | - | $2.21M | $2.64M | $1.95M | - |
| R&D | $583.0K | - | $550.0K | $852.0K | $988.0K | - | $777.0K | $1.12M | $1.14M | - |
| SG&A | $4.06M | - | $2.09M | $2.25M | $2.55M | - | $2.31M | $2.01M | $2.25M | - |
| Total Operating Expenses | $6.69M | - | $3.95M | $4.79M | $5.25M | - | $4.85M | $4.97M | $5.21M | - |
| D&A | $454.0K | - | - | - | $378.0K | - | - | - | $406.0K | - |
| Operating Income | ($5.62M) | - | ($1.40M) | ($3.98M) | ($3.44M) | - | ($2.64M) | ($2.33M) | ($3.26M) | - |
| Interest Expense | $143.0K | - | $18.0K | $65.0K | $57.0K | - | $79.0K | $74.0K | $57.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.88M) | - | ($1.42M) | ($2.71M) | ($2.89M) | - | ($2.07M) | ($2.42M) | ($3.43M) | - |
| EPS - Basic | ($2.04) | - | ($0.54) | ($1.24) | ($27.00) | - | ($22.50) | ($29.25) | ($45.00) | - |
| EPS - Diluted | ($2.04) | - | ($0.54) | ($1.24) | ($27.00) | - | ($22.50) | ($29.25) | ($45.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.99M | $1.17M | $2.72M | $5.24M | $8.05M | $6.49M | $8.29M | $5.88M | $8.80M | $8.64M |
| Accounts Receivable | $4.54M | $7.31M | $6.05M | $4.53M | $6.46M | $7.24M | $6.96M | $6.52M | $5.77M | $5.64M |
| Inventory | $4.65M | $4.82M | $5.02M | $5.44M | $4.96M | $4.57M | $5.03M | $4.97M | $5.11M | $5.05M |
| Accounts Payable | $2.11M | $1.43M | $1.66M | $1.45M | $2.00M | $1.55M | $1.81M | $2.13M | $1.88M | $1.85M |
| Current Assets | $14.05M | $14.05M | $14.80M | $15.97M | $20.07M | $18.84M | $21.07M | $18.64M | $20.52M | $20.21M |
| Total Assets | $19.67M | $20.11M | $21.66M | $23.17M | $27.31M | $26.65M | $29.21M | $26.98M | $28.96M | $28.92M |
| Current Liabilities | $9.09M | $8.64M | $8.94M | $6.71M | $8.55M | $7.54M | $7.51M | $7.70M | $7.31M | $8.12M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $13.93M | $11.08M | $11.98M | $12.24M | $14.62M | $13.95M | $14.34M | $14.93M | $14.91M | $16.31M |
| Stockholders' Equity | $2.09M | $9.03M | $9.68M | $10.93M | $12.69M | $12.71M | $14.87M | $12.06M | $14.05M | $12.61M |
| Retained Earnings | ($269.28M) | ($262.40M) | ($257.72M) | ($256.30M) | ($253.59M) | ($250.47M) | ($247.06M) | ($244.99M) | ($242.57M) | ($239.15M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.12M) | - | - | - | ($1.97M) | - | - | - | ($3.47M) | - |
| Investing Cash Flow | $0 | - | - | - | ($10.0K) | - | - | - | ($8.0K) | - |
| Financing Cash Flow | $4.95M | - | - | - | $3.53M | - | - | - | $3.66M | - |
| CapEx | $0 | - | - | - | $10.0K | - | - | - | $8.0K | - |
| Free Cash Flow | ($2.12M) | - | - | - | ($1.98M) | - | - | - | ($3.47M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.31 | - | - | - | 0.68 | - | - | - | 1.01 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -35.0% | - | -6.6% | -11.7% | -10.6% | - | -7.1% | -9.0% | -11.8% | - |
| Return on equity | -329.4% | - | -14.7% | -24.8% | -22.8% | - | -13.9% | -20.0% | -24.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.55 | 1.63 | 1.66 | 2.38 | 2.35 | 2.50 | 2.81 | 2.42 | 2.81 | 2.49 |
| Quick ratio | 1.03 | 1.07 | 1.09 | 1.57 | 1.77 | 1.89 | 2.14 | 1.77 | 2.11 | 1.87 |
| Cash ratio | 0.44 | 0.14 | 0.30 | 0.78 | 0.94 | 0.86 | 1.10 | 0.76 | 1.20 | 1.06 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -39.3x | - | -77.9x | -61.2x | -60.4x | - | -33.4x | -31.6x | -57.1x | - |
| Equity multiplier | 9.41 | 2.23 | 2.24 | 2.12 | 2.15 | 2.10 | 1.96 | 2.24 | 2.06 | 2.29 |
| Liabilities / Assets | 0.71 | 0.55 | 0.55 | 0.53 | 0.54 | 0.52 | 0.49 | 0.55 | 0.51 | 0.56 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.23 | - | 0.33 | 0.23 | 0.32 | - | 0.38 | 0.47 | 0.35 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 1590d | - | 1093d | 1604d | 1154d | - | 956d | 785d | 1033d | - |
| Days payable outstanding | 721d | - | 361d | 427d | 465d | - | 344d | 335d | 379d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | 23.8x | 23.9x | 25.3x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -40.5% | - | 15.4% | -68.9% | -7.4% | - | -10.1% | 17.0% | -2.5% | - |
| Operating income growth (YoY) | -63.3% | - | 46.9% | -70.2% | -5.7% | - | 10.0% | 45.5% | 26.8% | - |
| Net income growth (YoY) | -138.2% | - | 31.4% | -12.1% | 15.7% | - | 38.4% | 42.9% | 21.9% | - |
| EPS growth (YoY) | 92.4% | - | 97.6% | 95.8% | 40.0% | - | -9275.0% | -9335.5% | -13536.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -7.5% | - | - | - | 43.1% | - | - | - | 17.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -83.5% | -29.0% | -34.9% | -9.4% | -9.7% | 0.8% | -2.5% | -32.3% | -34.0% | -50.5% |
Peer comparison
Same SIC group: General Industrial Machinery & Equipment, NEC
Comparing EKSO BIONICS HOLDINGS against the 5 most active filers in the same SIC group.